The study is an open label, multi-center, randomized trial in the Netherlands and Belgium. CSF was sampled in 11 volunteers at 0 and 12 weeks, showing an undetectable viral load in CSF in most patients in both groups at 12 weeks.
T is well tolerated.
The antiretroviral effect does not differ significantly between the two study arms over the first 18 weeks. Twenty-four weeks results and more CSF data will be presented.